drugset / Trial / NCT01082120

Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus

NCT01082120

Phase 1 Completed 28 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine whether administration of AZD1656 will affect the pharmacokinetics of Pioglitazone and vice versa in patients with Type 2 Diabetes Mellitus.

Timeline

Start
2010-02
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1656 Small molecule Oral
Subject Pioglitazone Small molecule Oral